ACHILLION PHARMACEUTICALS INC (ACHN) Stock News
NASDAQ:ACHN - Nasdaq -
ACHN Latest News, Press Relases and Analysis
Boutique Firms Steal the Show on Year’s Top Health-Care Deal
Boutique advisory firms are taking most of the limelight on the year’s biggest health-care deal.
The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 27) 10X Genomics Inc (NASDAQ...
71 Biggest Movers From Yesterday
Gainers Cleveland BioLabs, Inc. (NASDAQ: CBLI) shares climbed 210.6% to close at $4.10 on Monday. The stock has attracted investor interest amid the coronavirus outbreak due to...
Best & Worst Performing Small Cap Stocks for January 27, 2020
MGEN – MGEN leads the way today as the best performing small cap stock, closing up 50.52%.
Will Soliris, Ultomiris Drive Alexion's (ALXN) Q4 Earnings?
Alexion Inc.'s (ALXN) fourth-quarter 2019 results, scheduled to be reported on Jan 30, are likely to reflect solid performance of key drugs.
Achillion up 16% premarket on advancement of Alexion tie-up
Achillion Pharmaceuticals (NASDAQ:ACHN) is up 16% premarket on robust volume on the heels of its disclosure that the U.S. Federal Trade Commission has granted early termination of the waiting period f
Mentions: ALXN
Achillion +15.7% after FTC deal clearance
Achillion Pharmaceuticals (NASDAQ:ACHN) is up 15.7% in robust postmarket action after the Federal Trade Commission granted early termination of the HSR waiting period in its acquisition by Alexion Ph
Mentions: ALXN
WPG, ACHN, HDB and CANF among after hours movers
Gainers: ACHN +14.1%. TWI +4.9%. SEAC +4.7%. FLDM +4.5%. WPG +3.6%.Losers: CANF -14%. TX -4.3%. HDB -3.4%. SALT -1.8%. APT -1.6%.
Achillion shareholders back Alexion takeover
Achillion Pharmaceuticals (ACHN +0.3%) stockholders voted overwhelmingly in favor of Alexion Pharmaceuticals' (ALXN +0.6%) $6.30/share bid (~$930M).The transaction includes contingent value rights (CV
Mentions: ALXN
Why Is Achillion (ACHN) Down 2.8% Since Last Earnings Report?
Achillion (ACHN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
5 Stocks That Pushed Russell 2000 ETF Higher
Inside the best performing stocks of the Russell 2000 ETF.
Achillion's (ACHN) Danicopan Gets EMA's PRIME Tag for PNH
Achillion's (ACHN) lead pipeline candidate danicopan receives PRIME status from the EMA as a treatment option for PNH in patients, who are not adequately responding to a C5 inhibitor.
EMA grants PRIME designation to Achillion's danicopan
The European Medicines Agency (EMA) has granted access to Achillion Pharmaceuticals (NASDAQ:ACHN) to support through the PRIME (PRIority MEdicines) program for danicopan (ACH-4471) in the trea
EMA grants PRIME designation to Achillion's danicopa
The European Medicines Agency (EMA) has granted access to Achillion Pharmaceuticals (NASDAQ:ACHN) to support through the PRIME (PRIority MEdicines) program for danicopan (ACH-4471) in the trea
Alexion (ALXN) Up 10 % YTD on Soliris & Ultomiris Strength
Alexion's (ALXN) stock rises 10% in the year so far as Soliris maintains momentum and Ultomiris gains further traction.
This $2.7 Billion Deal Is a Shot Across the Bow for Big Pharma
Folks who haven’t been paying attention to the absolutely huge potential happening in biotech stocks right now -- both in the U.S. and other parts of the world -- have been put on notice.
Pharma Sector Tops in October: Best ETFs & Stocks
Pharma sector wins in October, making these ETFs and stocks winners.
Achillion Pharmaceuticals EPS beats by $0.02
Achillion Pharmaceuticals (NASDAQ:ACHN): Q3 GAAP EPS of -$0.14 beats by $0.02.Cash & equivalents of $229M.The company's acquisition by Alexion is expected to close by 1H20.Press Release